E Fund Management Co., Ltd. Prothena Corp Public LTD CO Transaction History

E Fund Management Co., Ltd.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$24.75 - $40.66 $80,289 - $131,901	3,244 Added 29.24%	14,340 $355,000
Q4 2023 Feb 06, 2024	BUY	$32.31 - $52.32 $98,125 - $158,895	3,037 Added 37.68%	11,096 $403,000
Q3 2023 Nov 13, 2023	BUY	$47.3 - $70.6 $77,193 - $115,219	1,632 Added 25.39%	8,059 $389,000
Q2 2023 Aug 11, 2023	SELL	$48.26 - $78.59 $78,277 - $127,472	-1,622 Reduced 20.15%	6,427 $439,000
Q1 2023 May 11, 2023	BUY	$46.97 - $58.27 $37,857 - $46,965	806 Added 11.13%	8,049 $390,000
Q4 2022 Feb 14, 2023	SELL	$52.05 - $65.0 $4,476 - $5,590	-86 Reduced 1.17%	7,243 $436,000
Q3 2022 Nov 14, 2022	SELL	$25.16 - $60.63 $50,722 - $122,230	-2,016 Reduced 21.57%	7,329 $444,000
Q2 2022 Aug 15, 2022	BUY	$22.73 - $39.98 $48,710 - $85,677	2,143 Added 29.76%	9,345 $254,000
Q1 2022 May 12, 2022	BUY	$30.27 - $49.22 $166,273 - $270,365	5,493 Added 321.42%	7,202 $263,000
Q1 2021 May 12, 2021	BUY	$11.0 - $28.24 $18,799 - $48,262	1,709 New	1,709 $42,000

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $714M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on E Fund Management Co., Ltd. with notifications on news.